PF-07901801
Showing 1 - 25 of 1,083
DLBCL Trial (maplirpacept (PF-07901801), Glofitamab, Obinutuzumab)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- maplirpacept (PF-07901801)
- +2 more
- (no location specified)
May 30, 2023
DLBCL Trial in San Juan (PF-07901801, Tafasitamab, Lenalidomide)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- PF-07901801
- +2 more
-
San Juan, Puerto RicoAuxilio Mutuo Cancer Center
Jan 19, 2023
Non-Hodgkin Lymphoma, Multiple Myeloma Trial in China (Maplirpacept)
Not yet recruiting
- Non-Hodgkin Lymphoma
- Multiple Myeloma
-
Beijing, Beijing, China
- +3 more
May 31, 2023
Healthy Participants Trial (Single dose of PF-07220060 as first Tablet Formulation, Single dose of PF-07220060 as second Tablet
Not yet recruiting
- Healthy Participants
- Single dose of PF-07220060 as first Tablet Formulation
- +3 more
- (no location specified)
Jun 20, 2023
Atopic Dermatitis Trial in United States (PF-07275315, PF-07264660, Placebo)
Not yet recruiting
- Atopic Dermatitis
- PF-07275315
- +2 more
-
Huntington Beach, California
- +3 more
Aug 21, 2023
Hemiparesis;Poststroke/CVA Trial in Créteil (Eccentric training, Conventional therapy)
Recruiting
- Hemiparesis;Poststroke/CVA
- Eccentric training
- Conventional therapy
-
Créteil, FranceWael Maktouf
Nov 16, 2023
Pulmonary Arterial Hypertension Trial (PF-07868489, Placebo for PF-07868489)
Not yet recruiting
- Pulmonary Arterial Hypertension
- PF-07868489
- Placebo for PF-07868489
- (no location specified)
Nov 14, 2023
Hemolysis During Pulsed-field and Radiofrequency Ablation
Not yet recruiting
- Atrial Fibrillation
- +2 more
- Pulsed-field ablation
- Radiofrequency ablation
-
Prague, CzechiaCardiocenter, 3rd Medical School, Charles University and Univers
Oct 20, 2023
Breast Cancer, Ovarian Cancer, Liposarcoma Trial (PF-07224826, Fulvestrant)
Not yet recruiting
- Breast Cancer
- +5 more
- PF-07224826
- Fulvestrant
- (no location specified)
Jun 7, 2023
Pelvic Floor Disorders Trial in Palma De Mallorca (Pelvic floor muscle training with biofeedback device, Pelvic floor muscle
Not yet recruiting
- Pelvic Floor Disorders
- Pelvic floor muscle training with biofeedback device
- +2 more
-
Palma De Mallorca, Balearic Islands, SpainUniversity of the Balearic Islands
Aug 29, 2023
Renal Impairment Trial (Drug: PF-07923568)
Not yet recruiting
- Renal Impairment
- Drug: PF-07923568
- (no location specified)
Sep 7, 2023
Healthy Trial in New Haven (PF-07328948, Placebo)
Recruiting
- Healthy
- PF-07328948
- Placebo
-
New Haven, ConnecticutNew Haven Clinical Research Unit
Jan 5, 2023
Overweight, Obesity Trial in New Haven (Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg))
Recruiting
- Overweight
- Obesity
- Formulation A (PF-07081532 20 mg plus 60 mg)
- Formulation B (PF-07081532 80 mg)
-
New Haven, ConnecticutNew Haven Clinical Research Unit
Jan 25, 2023
Plantar Fasciitis Trial in Boston (Orthotic)
Terminated
- Plantar Fasciitis
- Orthotic
-
Boston, MassachusettsMassachusetts General Hospital
Oct 31, 2023
Presbyopia Trial in Crystal River (BRIMOCHOL™ PF, Carbachol PF, Vehicle)
Recruiting
- Presbyopia
- BRIMOCHOL™ PF
- +2 more
-
Chandler, Arizona
- +42 more
Sep 30, 2022
Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer,
Recruiting
- Locally Advanced or Metastatic ER+ HER2- Breast Cancer
- +2 more
- PF-07248144
- +3 more
-
Scottsdale, Arizona
- +45 more
Dec 11, 2022
Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer Trial in Japan, United States (PF-07265028, Sasanlimab)
Recruiting
- Advanced Solid Tumors
- +5 more
- PF-07265028
- Sasanlimab
-
Scottsdale, Arizona
- +7 more
Jan 23, 2023
Progressive Pulmonary Fibrosis, Interstitial Lung Disease Trial (Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic
Not yet recruiting
- Progressive Pulmonary Fibrosis
- Interstitial Lung Disease
- Placebo
- +2 more
- (no location specified)
Jul 5, 2023
Breast Cancer, Solid Tumors Trial in Boston, Grand Rapids, Houston (PF-07220060 + PF-07104091 combination dose escalation,
Recruiting
- Breast Cancer
- Solid Tumors
- PF-07220060 + PF-07104091 combination dose escalation
- +2 more
-
Grand Rapids, Michigan
- +1 more
Jun 28, 2022
Interstitial Lung Diseases Trial in Wenzhou (Anlotinib, Placebo)
Recruiting
- Interstitial Lung Diseases
- Anlotinib
- Placebo
-
Wenzhou, Zhejiang, ChinaThe First Affiliated Hospital of Wenzhou Medical University
Apr 13, 2023